Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Receptos reports third quarter 2013 financial results
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Ofatumumab Dose-finding in RRMS Patients
National Cancer Institute Search for Clinical Trials
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Current and future disease-modifying therapies in multiple sclerosis.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
EFNS 2012
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.

Pages